Skip to main content
. Author manuscript; available in PMC: 2016 Aug 22.
Published in final edited form as: Cancer. 2010 Aug 15;116(16):3852–3861. doi: 10.1002/cncr.25123

Table 4.

Selected Adverse Events Associated With Dasatinib

No. of Patients (%)
CML in Myeloid Blast Phase CML in Lymphoid Blast Phase
Dasatinib 140 mg Dasatinib 70 mg BID Dasatinib 140 mg Dasatinib 70 mg BID
Adverse Events
Nonhematologic
All
Grades
Grade
3/4
All
Grades
Grade
3/4
All
Grades
Grade
3/4
All
Grades
Grade
3/4
No. of patients 74 74 33 28
Fluid retention 25 (34) 4 (5) 23 (31) 8 (11) 7 (21) 2 (6) 11 (39) 2 (7)
Pleural effusion 15 (20) 4 (5) 13 (18) 4 (5) 7 (21) 2 (6) 10 (36) 1 (4)
Superficial edema 10 (14) 0 (0) 10 (14) 2 (3) 1 (3) 0 (0) 7 (25) 0 (0)
Other 7 (9) 1 (1) 7 (9) 4 (5) 0 (0) 0 (0) 3 (11) 1 (4)
Diarrhea 15 (20) 4 (5) 15 (20) 2 (3) 6 (18) 0 (0) 11 (39) 2 (7)
Headache 13 (18) 1 (1) 9 (12) 1 (1) 5 (15) 1 (3) 7 (25) 2 (7)
Bleeding 14 (19) 7 (9) 20 (27) 7 (9) 8 (24) 3 (9) 6 (21) 1 (4)
Other 9 (12) 2 (3) 10 (14) 1 (1) 4 (12) 1 (3) 4 (14) 0 (0)
GI bleeding 7 (9) 5 (7) 11 (15) 6 (8) 3 (9) 1 (3) 1 (4) 0 (0)
CNS bleeding 0 (0) 0 (0) 2 (3) 0 (0) 1 (3) 1 (3) 1 (4) 1 (4)
Nausea 17 (23) 1 (1) 9 (12) 0 (0) 7 (21) 1 (3) 7 (25) 1 (4)
Fatigue 15 (20) 1 (1) 8 (11) 0 (0) 3 (9) 1 (3) 4 (14) 2 (7)
Rash 11 (15) 1 (1) 9 (12) 0 (0) 7 (21) 0 (0) 3 (11) 0 (0)
Febrile neutropenia 9 (12) 9 (12) 5 (7) 5 (7) 4 (12) 4 (12) 3 (11) 3 (11)
No. of Patients (%)
CML in Myeloid Blast Phase CML in Lymphoid Blast Phase
Dasatinib 140 mg Dasatinib 70 mg BID Dasatinib 140 mg Dasatinib 70 mg BID
Cytopenias All
Grades
Grade
3/4
All
Grades
Grade
3/4
All
Grades
Grade
3/4
All
Grades
Grade
3/4
No. of patients 72 73 33 28
Neutropenia 65 (90) 57 (79) 65 (89) 54 (74) 31 (94) 26 (79) 26 (93) 24 (86)
Thrombocytopenia 67 (93) 58 (81) 67 (92) 58 (80) 32 (97) 28 (85) 28 (100) 24 (86)
Anemia 70 (97) 55 (76) 73 (100) 57 (78) 33 (100) 17 (52) 28 (100) 14 (50)
Leukocytopenia 60 (83) 44 (61) 61 (84) 44 (60) 30 (91) 26 (79) 26 (93) 18 (64)

CML indicates chronic myeloid leukemia; QD, once daily; BID, twice daily; GI, gastrointestinal; CNS, central nervous system.